41results about How to "Inhibition of fibrillation" patented technology

A method and apparatus are provided for protecting cardiac tissue from insult. The method comprises identifying the occurrence of an insult, such as a heart attack, and delivering electrical stimulation to one or more predetermined nerves in a patient's body in response to identifying the occurrence of the insult. The stimulation may be provided at the spinal canal or on the chest wall of the patient through cutaneous electrodes.

A RF catheter system includes a catheter with a proximal portion, a distal portion having a distal end and a lumen extending from the proximal portion to the distal portion. Inner and outer coaxially aligned conductors extend within the catheter and are coaxial with the lumen. A deflectable catheter guide is disposed within the catheter lumen and extends proximally within the catheter lumen and terminates distally of the distal end of the catheter to define a biological ablation pathway. A radio-frequency antenna is disposed at the distal portion of the catheter and is in electrical communication with the inner and outer coaxially aligned conductors. The radio-frequency antenna is adaptable to receive and transmit radio-frequency energy for ablating biological tissue along the ablation pathway.

A RF catheter system includes a catheter with a proximal portion, a distal portion having a distal end and a lumen extending from the proximal portion to the distal portion. Inner and outer coaxially aligned conductors extend within the catheter and are coaxial with the lumen. A deflectable catheter guide is disposed within the catheter lumen and extends proximally within the catheter lumen and terminates distally of the distal end of the catheter to define a biological ablation pathway. A radio-frequency antenna is disposed at the distal portion of the catheter and is in electrical communication with the inner and outer coaxially aligned conductors. The radio-frequency antenna is adaptable to receive and transmit radio-frequency energy for ablating biological tissue along the ablation pathway.

A device and system are disclosed for selective inflation of an inflatable body, such as a balloon, received through an oral cavity and into the esophagus of a patient. The inflatable body is operably coupled to a pressurized fluid source. The inflatable body has a relatively flexible portion and a relatively inflexible portion. When pressurized fluid is delivered to the body to inflate the body, the flexible portion expands more than the inflexible portion, resulting in asymmetrical expansion and movement of the esophagus away from the ablation site to avoid accidental injury while performing a procedure on the patient's left atrium. This movement may be opposite from or directly away from the heart or, alternatively, may be sideways relative to the heart to a location in which the esophagus is interposed between the ablation site and the phrenic nerve. The supplied fluid may be radio-opaque liquid to allow for imaging thereof to assist in positioning the balloon. The liquid may additionally be relatively cool as compared to the patient's body temperature so serve as a heat sink against heat applied to surrounding areas.

A RF catheter system includes a catheter with a proximal portion, a distal portion having a distal end and a lumen extending from the proximal portion to the distal portion. Inner and outer coaxially aligned conductors extend within the catheter and are coaxial with the lumen. A deflectable catheter guide is disposed within the catheter lumen and extends proximally within the catheter lumen and terminates distally of the distal end of the catheter to define a biological ablation pathway. A radio-frequency antenna is disposed at the distal portion of the catheter and is in electrical communication with the inner and outer coaxially aligned conductors. The radio-frequency antenna is adaptable to receive and transmit radio-frequency energy for ablating biological tissue along the ablation pathway.

The present invention provides methods for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject. The present invention further provides methods for treating and preventing atrial and ventricular cardiac arrhythmias, heart failure, and exercise-induced sudden cardiac death in a subject. Additionally, the present invention provides use of JTV-519 in a method for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject who has, or is a candidate for, atrial fibrillation. Also provided are uses of 1,4-benzothiazepine derivatives in methods for treating and preventing atrial and ventricular cardiac arrhythmias and heart failure in a subject, and for preventing exercise-induced sudden cardiac death. The present invention also provides methods for identifying agents for use in treating and preventing atrial fibrillation and heart failure, and agents identified by these methods.

The present invention provides an electrical block implant sized and shaped for securement at the perimeter of the pulmonary ostium of the left atrium. By utilizing various expandable ring designs and optional anchoring mechanisms, the present invention causes even, circular scarring around the perimeter of the pulmonary ostium, achieving reliable blocking of aberrant electrical signals responsible for atrial fibrillation.

The present invention provides an electrical block implant sized and shaped for securement at the perimeter of the pulmonary ostium of the left atrium. By utilizing various expandable ring designs and optional anchoring mechanisms, the present invention causes even, circular scarring around the perimeter of the pulmonary ostium, achieving reliable blocking of aberrant electrical signals responsible for atrial fibrillation.

Devices and methods to treat atrial fibrillation via inhibition of nerves which innervate the pulmonary vein are provided.

The present invention provides a fiber-reinforced glass having excellent heat resistance and toughness, or a composite comprising a heat-resistant fiber and a siloxane polymer, which has a modified surface structure and is useful as a heat-resistant fiber.

The present invention provides a fiber-reinforced glass having excellent heat resistance and toughness, or a composite comprising a heat-resistant fiber and a siloxane polymer, which has a modified surface structure and is useful as a heat-resistant fiber.

The present invention provides an electrical block implant sized and shaped for securement at the perimeter of the pulmonary ostium of the left atrium. By utilizing various expandable ring designs and optional anchoring mechanisms, the present invention causes even, circular scarring around the perimeter of the pulmonary ostium, achieving reliable blocking of aberrant electrical signals responsible for atrial fibrillation.

Effective and safe pharmaceutical composition and method for treating atrial fibrillation are described. The combined use of dofetilide and mexiletine resulted in an enhanced efficacy in the prevention and treatment of atrial fibrillation with markedly reduced risk of the life-threatening ventricular arrhythmia TdP.

The present invention relates to compositions and methods for the prevention and treatment of atrial fibrillation. In particular, the present invention provides therapeutic agents for the treatment and prevention of persistent and permanent atrial fibrillation and prevention of progression of atrial fibrillation to permanent atrial fibrillation.

The present invention provides an electrical block implant sized and shaped for securement at the perimeter of the pulmonary ostium of the left atrium. By utilizing various expandable ring designs and optional anchoring mechanisms, the present invention causes even, circular scarring around the perimeter of the pulmonary ostium, achieving reliable blocking of aberrant electrical signals responsible for atrial fibrillation.

D-ribose, given in doses of five to 15 grams daily, reduces or prevents the occurrence of atrial fibrillation in persons experiencing atrial fibrillation.

The present invention is directed to novel pharmaceutical combinations including compositions and kits comprising bretylium as the active ingredient, as well as methods for preventing and / or treating conditions related to the cardiovascular system using such novel pharmaceutical combinations.

The present invention relates to evaluating the effect of physiological conditions on the occurrence of ventricular fibrillation, identifying strategies for treatment or prevention of ventricular fibrillation or ventricular tachycardia, and evaluating a subject for induction of ventricular fibrillation from a condition of ventricular tachycardia.

The present invention relates to the preparation and use of polymer complements to [beta]-amyloid peptides [Alpha][beta] for detecting soluble or aggregated [Alpha][beta] in fluid samples or for treating a subject having a neurodegenerative disease.

The present invention relates to evaluating the effect of physiological conditions on the occurrence of ventricular fibrillation, identifying strategies for treatment or prevention of ventricular fibrillation or ventricular tachycardia, and evaluating a subject for induction of ventricular fibrillation from a condition of ventricular tachycardia.

The present invention relates to the use of a plant material of the species Trichilia sp., alone or in association with one or more of the following plants: Paullinia cupana (Sapindaceae), Croton moritibensis (Euphorbiaceae) and Zingiber officinale (Zingiberaceae) in the treatment, reversion, combat and / or prevention of ventricular fibrillation. A product particularly embraced by the present invention comprises the plant material of the species Trichilia sp., alone or in association with extracts from other plants. The invention also refers to the use of one or more fractions of plant extract from such plant material, particularly of Trichilia catigua A. Juss, and of one or more subfractions of said fractions in the treatment, combat, prevention and / or reversion of ventricular fibrillation.

Effective and safe pharmaceutical composition and method for treating atrial fibrillation are described. The combined use of dofetilide and mexiletine resulted in an enhanced efficacy in the prevention and treatment of atrial fibrillation with markedly reduced risk of the life-threatening ventricular arrhythmia TdP.

The present invention provides methods for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject. The present invention further provides methods for treating and preventing atrial and ventricular cardiac arrhythmias, heart failure, and exercise-induced sudden cardiac death in a subject. Additionally, the present invention provides use of JTV-519 in a method for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject who has, or is a candidate for, atrial fibrillation. Also provided are uses of 1,4-benzothiazepine derivatives in methods for treating and preventing atrial and ventricular cardiac arrhythmias and heart failure in a subject, and for preventing exercise-induced sudden cardiac death. The present invention also provides methods for identifying agents for use in treating and preventing atrial fibrillation and heart failure, and agents identified by these methods.

The present invention relates to cellulose fibers with an enhanced metering capability, a process for the production of these and the use of these for the reinforcement of compound materials, in particular thermoplastic polymers.

D-ribose, given in doses of five to 15 grams daily, reduces or prevents the occurrence of atrial fibrillation in persons experiencing atrial fibrillation.

The present invention relates to cellulose fibers with an enhanced metering capability, a process for the production of these and the use of these for the reinforcement of compound materials, in particular thermoplastic polymers.